Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers

References

• Mitchell AJ, Krull EA. Alopecia areata pathogenesis and treatment. J Am Acad Dermatol. 1984;11:763–775.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Kalish RS. Alopecia areata: A tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64–69.
   PubMed Web of Science ®Google Scholar
• Ito T, Ito N, Saatoff M, Hashizume H, Fukimazu H. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–1206.
   PubMed Web of Science ®Google Scholar
• Ito T, Aoshima M, Ito N, Uchiyama I. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch Dermatol Res. 2009;301:373–380.
   PubMed Web of Science ®Google Scholar
• McElwee K, Spiers E, Oliver R. Partial model for alopecia areata after in vivo depletion of CD4 T cells. Br J Dermatol. 1999;140:432–437.
   PubMed Web of Science ®Google Scholar
• Simonetti O, Lucarini G, Bernardini M, Simoncini C, Biagini G, Offidani A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: An immunohistochemical study. Br J Dermatol. 2004;150:940–948.
   PubMed Web of Science ®Google Scholar
• Sehgal V, Srivastava G, Dogra S. Tacrolimus: Approved and unapproved dermatologic indications/uses – Physicians sequential literature survey: Part II. Skinmed. 2008;7:73–78.
   PubMedGoogle Scholar
• Avgerinou G, Gregoriou S, Rigopoulas D, Sratigos A, Kalogeromitros D, Katsambas A. Alopecia areata topical immunotherapy with diphencyprone. J Eur Acad Dermatol Venereol. 2008;22:320–323.
   PubMed Web of Science ®Google Scholar
• Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549–566.
   PubMed Web of Science ®Google Scholar
• Pericin M, Truebe R. Topical immunotherapy of severe alopecia areata with diphencyprone evaluation of 68 cases. Dermatology. 1998;196:418–421.
   PubMed Web of Science ®Google Scholar
• Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137:1063–1068.
   PubMedGoogle Scholar
• Cotelessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44:73–76.
   PubMed Web of Science ®Google Scholar
• McDonald Hull S, Norris JF. Diphencyprone in the treatment of long standing alopecia areata. Br J Dermatol. 1988;119:367–374.
   PubMed Web of Science ®Google Scholar
• Firooz A, Bouzari N, Mojtahed F, Pazoki-Toroudi H, Nassiri-Kashini M, Davoudi M, Dawlati Y. Topical immunotherapy with diphencyprone in the treatment of extensive and or long lasting alopecia areata. J Eur Acad Dermatol Venereol. 2005;19:393–394.
   PubMed Web of Science ®Google Scholar
• Shapiro J, Tan J, Ho V, Abbott F, Tron V. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil. J Am Acad Dermatol. 1998;29:729–735.
   Google Scholar
• Van der Steen P, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin. 1993;11:619–622.
   PubMed Web of Science ®Google Scholar
• Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: Response to treatment with diphencyprone. Br J Dermatol. 1991;125:164–168.
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Happle R. Topical immunotherapy in alopecia areata. What, how and why? Dermatol Clin. 1996;14:739–744.
   PubMed Web of Science ®Google Scholar
• Freyschmidt-Paul P, Hamm H, Happle R, Hoffmann R. Pronounced perifollicular lymphocytic infiltrate in alopecia areata are associated with poor treatment response to diphencyprone. Eur J Dermatol. 1999;9:111–114.
   PubMed Web of Science ®Google Scholar
• Kehren J, Desvignes C, Krasteva M, Ducluzeau M, Assossou O, Horand F, Cytotoxicity is mandatory for CD8 T cell mediated contact hypersensitivity. J Exp Med. 1999;189:779–786.
   PubMed Web of Science ®Google Scholar
• Thein C, Strange P, Hansen ER, Baadsgaard O. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res. 1997;289:384–388.
   PubMed Web of Science ®Google Scholar
• Tobin D, Gardener S, Lindsey N, Hoffmann R, Happle R. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata. Eur J Dermatol. 2002;12:327–334.
   PubMed Web of Science ®Google Scholar
• Freyschmidt-Paul P, Sundberg J, Happle R, Mclwee K, Metz S, Boggers D, Successful treatment of alopecia areata like hair loss with the contact sensitizers quaric acid dibutyl ester in C3H/HEL mice. J Invest Dermatol. 1999;113:61–68.
   PubMed Web of Science ®Google Scholar
• Freyschmidt-Paul P, Hoffmann R, Levin E, Sundberg R, Happle R, Mclwee K. Current and potential agents for the treatment of alopecia areata. Curr Pharm Des. 2001;7:213–270.
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Wenzel E, Huth A, Henninger HP, Steen P, Schaufele M, Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyprone. J Invest Dermatol. 1994;103:530–533.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennet B, Fidget G, de Vries J. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209–1220.
   PubMed Web of Science ®Google Scholar
• Seifert M, Sterry L, Effenberger E, Rexin A, Friedrich M, Haeussler-Quade A, The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by direct effect on human keratinocytes. Arch Dermatol Res. 2000;292:164–172.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Kam Y, Assy B, Kalish R. Alopecia areata induced in C3H/Hej mice by interferon gamma: Evidence for loss of immune privilege. J Invest Dermatol. 2005;124:288–289.
   PubMed Web of Science ®Google Scholar
• McElwee J, Hoffmann R. Alopecia areata in animal models. Clin Exp Dermatol. 2002;27:410–417.
   PubMed Web of Science ®Google Scholar
• Price V, Willey A, Chen B. Topical tacrolimus in the treatment of alopecia areata. J Am Acad Dermatol. 2005;52:138–139.
   PubMed Web of Science ®Google Scholar
• Feldman K, Kunte C, Wollenberg A, Wolff H. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol. 2002;147:1031–1032.
   PubMed Web of Science ®Google Scholar
• Thiers B. Topical tacrolimus: Treatment failure in a patient with alopecia areata. Arch Dermatol. 2000;136:124.
   PubMed Web of Science ®Google Scholar
• Mcelwee K, Rushton D, Trachy R, Oliver R. Topical FK506: A potent immunotherapy for alopecia areata. Studies using the Dundee experimental bald rat model. Br J Dermatol. 1997;137:491–497.
   PubMed Web of Science ®Google Scholar
• McElwee K, Spiers E, Oliver R. Partial model for alopecia areata after in vivo depletion of CD4 cells. Br J Dermatol. 1999;140:432–437.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Paul C, Duteil L. The new topical ascomycin derivative SCZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized double blind controlled study. Br J Dermatol. 2001;144:507–513.
   PubMed Web of Science ®Google Scholar
• Sehgal V, Srivastava G, Dogra S. Tacrolimus: Approved and unapproved dermatologic indications/uses – Physician's sequential literature survey; Part II. Skinmed. 2008;7:73–77.
   PubMedGoogle Scholar
• Happle R. Topical immunotherapy in alopecia areata. J Invest Dermatol. 1991;96:71S–72S.
   PubMed Web of Science ®Google Scholar